Analysts Are Bullish on Top Healthcare Stocks: InfuSystem Holdings (INFU), Jazz Pharmaceuticals (JAZZ)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on InfuSystem Holdings (INFU – Research Report) and Jazz Pharmaceuticals (JAZZ – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
InfuSystem Holdings (INFU)
Craig-Hallum analyst Matt Hewitt maintained a Buy rating on InfuSystem Holdings yesterday. The company’s shares closed last Tuesday at $8.60.
According to TipRanks.com, Hewitt is ranked 0 out of 5 stars with an average return of
InfuSystem Holdings has an analyst consensus of Strong Buy, with a price target consensus of $16.25, representing a 96.3% upside. In a report released yesterday, TipRanks – DeepSeek also reiterated a Buy rating on the stock with a $8.50 price target.
See today’s best-performing stocks on TipRanks >>
Jazz Pharmaceuticals (JAZZ)
Truist Financial analyst Joon Lee maintained a Buy rating on Jazz Pharmaceuticals today. The company’s shares closed last Tuesday at $173.83.
According to TipRanks.com, Lee is a top 100 analyst with an average return of
Currently, the analyst consensus on Jazz Pharmaceuticals is a Strong Buy with an average price target of $233.00, representing a 35.0% upside. In a report released today, TipRanks – OpenAI also upgraded the stock to Buy with a $191.00 price target.
